**Core Concept**
Leishmaniasis is a parasitic disease caused by Leishmania species, transmitted through the bite of infected sandflies. Treatment options involve various antiprotozoal and immunomodulatory agents to combat the disease, depending on the severity and type of Leishmaniasis.

**Why the Correct Answer is Right**
The treatment of Leishmaniasis involves a range of medications, including antimonials (e.g., sodium stibogluconate), amphotericin B, miltefosine, and paromomycin. These agents target the parasite at different stages of its life cycle, either by inhibiting its growth or by enhancing the host's immune response. **Amphotericin B** is particularly effective in treating visceral Leishmaniasis, a severe form of the disease.

**Why Each Wrong Option is Incorrect**
* **Option A:** **Miltefosine** is indeed used in the treatment of Leishmaniasis, particularly for cutaneous and visceral forms, making it an incorrect choice.
* **Option B:** **Paromomycin** is another antiprotozoal agent used in the treatment of Leishmaniasis, which also makes it an incorrect choice.
* **Option C:** **Sodium stibogluconate** is an antimonial agent used to treat Leishmaniasis, rendering it an incorrect choice.

**Clinical Pearl / High-Yield Fact**
When treating Leishmaniasis, it is essential to consider the severity and type of the disease, as well as the patient's immune status and potential side effects of the medication. Amphotericin B is generally recommended for visceral Leishmaniasis, while miltefosine and paromomycin are alternatives for cutaneous and mucocutaneous forms.

**Correct Answer:** A. Miltefosine.